In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude's Approvals Further Roil CRT Market

Executive Summary

The already hotly-contested high-voltage cardiac resynchronization therapy defibrillator (CRT-D) device market became even more competitive at the end of June with the long-anticipated FDA approval of two systems from St. Jude Medical Inc.

You may also be interested in...



St. Jude Becomes New Caridology Dealmaker, Buys Velocimed

Last summer, when St. Jude Medical announced that the company was creating a new division dedicated exclusively to interventional cardiology, the question was when would St. Jude do its first deal in that space. The answer came recently with St. Jude's acquisition of Velocimed.

St. Jude Medical: Dealing Its Way to the Top in AF

St. Jude Medical's recent announcement that it will acquire Endocardial Solutions represents the latest step in St. Jude's aggressive strategy to become a dominant player in the atrial fibrillation (AF) market.

The Redemption of St. Jude Medical

In the early 1990s, St. Jude Medical was the market leader in its sole product area: mechanical heart valves, which placed it among the most profitable of device companies. Demographics, however, limited heart valves' future growth opportunities and St. Jude needed to diversify, moving into cardiac rhythm management (CRM), cardiology catheters, and vascular access devices, while also expanding in cardiac surgery. The diversification process went anything but smoothly, the company missed its numbers, and investors were quick to punish St. Jude for its integration missteps. In the past year, however, the company has become one of Wall Street's few device darlings, ranking number one in 2000 for returns among device stocks. The company's growth is largely the result of sticking to a strategy that has St. Jude well-positioned in CRM's traditional markets, while also poised to pursue huge new opportunities in atrial fibrillation and, to a lesser degree, congestive heart failure. And St. Jude has not forgotten its base: cardiac surgery, where the company has introduced new sutureless anastomotic technology for minimally invasive coronary bypass surgery.

Topics

Related Companies

UsernamePublicRestriction

Register

IV002389

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel